BerGenBio: Bemcentinib in combination with low-dose chemotherapy achieves efficacy endpoint in AML patients
Phase II trial evaluating bemcentinib in combination with low-dose chemotherapy in AML patients unfit for intensive therapy Bemcentinib + low-dose cytarabine (LDAC) achieves efficacy endpoint, warrants further investigation · Three out of 10 evaluable patients (30%) reported Complete Responses (CR/CRi) · Responses occurred early, improved over time and included poor risk, previously treated patients · No overlapping or new toxicities observed Meanwhile, Company will proceed with late-stage bemcentinib monotherapy trial in R/R AML patients, expected for H2 2019; monotherapy